Iovance Biotherapeutics, Inc. (IOVA)
7.63
-0.46
(-5.69%)
USD |
NASDAQ |
Nov 12, 16:00
7.63
0.00 (0.00%)
After-Hours: 07:42
Iovance Biotherapeutics Enterprise Value : 3.198B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 3.198B |
| November 11, 2026 | 3.411B |
| November 10, 2026 | 3.406B |
| November 09, 2026 | 3.448B |
| November 06, 2026 | 3.388B |
| November 05, 2026 | 3.249B |
| November 04, 2026 | 3.693B |
| November 03, 2026 | 3.753B |
| November 02, 2026 | 3.378B |
| October 30, 2026 | 3.591B |
| October 29, 2026 | 4.091B |
| October 28, 2026 | 6.519B |
| October 27, 2026 | 6.413B |
| October 26, 2026 | 6.043B |
| October 23, 2026 | 6.186B |
| October 22, 2026 | 6.209B |
| October 21, 2026 | 6.431B |
| October 20, 2026 | 6.542B |
| October 19, 2026 | 6.242B |
| October 16, 2026 | 5.969B |
| October 15, 2026 | 6.478B |
| October 14, 2026 | 6.242B |
| October 13, 2026 | 6.376B |
| October 12, 2026 | 6.404B |
| October 09, 2026 | 6.431B |
| Date | Value |
|---|---|
| October 08, 2026 | 5.825B |
| October 07, 2026 | 5.643B |
| October 06, 2026 | 5.663B |
| October 05, 2026 | 6.214B |
| October 02, 2026 | 6.244B |
| October 01, 2026 | 6.251B |
| September 30, 2026 | 6.524B |
| September 29, 2026 | 6.294B |
| September 28, 2026 | 4.726B |
| September 25, 2026 | 4.731B |
| September 24, 2026 | 4.640B |
| September 23, 2026 | 4.364B |
| September 22, 2026 | 4.568B |
| September 21, 2026 | 4.364B |
| September 18, 2026 | 4.391B |
| September 17, 2026 | 4.287B |
| September 16, 2026 | 4.219B |
| September 15, 2026 | 3.988B |
| September 14, 2026 | 3.943B |
| September 11, 2026 | 3.644B |
| September 10, 2026 | 3.436B |
| September 09, 2026 | 3.567B |
| September 08, 2026 | 3.689B |
| September 04, 2026 | 3.730B |
| September 03, 2026 | 3.689B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AVITA Medical, Inc. | 538.23M |
| Halozyme Therapeutics, Inc. | 13.65B |
| CareDx, Inc. | 3.965B |
| Merck & Co., Inc. | 406.57B |
| SELLAS Life Sciences Group, Inc. | 1.484B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -22.27M |
| Revenue (Quarterly) | 121.47M |
| Total Expenses (Quarterly) | 143.74M |
| EPS Diluted (Quarterly) | -0.0488 |
| Gross Profit Margin (Quarterly) | 52.64% |
| Profit Margin (Quarterly) | -18.33% |
| Earnings Yield | -6.81% |
| Normalized Earnings Yield | -6.809 |